Brain Electrophysiology in Pharma: Pharmacodynamic effects of dopamine receptor modulators in the rat striatum.
Philipp Schoenenberger

Brain diseases affect millions of children and adults worldwide, but despite the high unmet medical need, the development of novel therapeutics has been slow and difficult. I will demonstrate how at Roche we perform electrophysiological recordings in rodents to support the development of novel drugs for diseases such as Parkinson´s and schizophrenia. The main focuses of our work is to provide evidence for functional target engagement in key brain areas implicated in disease. I will illustrate this taking the dopaminergic system as an example. In addition, I will outline how we aim to bridge the gap between preclinical and clinical research by
developing translational EEG biomarkers.

Friday 23rd of June 2017, Mondi 2
5 pm: Scientific talk
5:30 pm: Q&A session about career development
6:00 pm: Refreshments

IST Alumni! Philipp Schönenberger:
• Postdoc in the Csicsvari Group from 2011 to 2015.
• Research scientist for Roche in Basel since 2015.
• His field: preclinical drug discovery in neuroscience with a focus on in vivo electrophysiology, optogenetics, and data analysis.